معرفی
Maike Buchner is a research group leader at the Technical University of Munich (TUM), School of Medicine, based at the Institute for Clinical Chemistry and Pathobiochemistry within TranslaTUM, the Central Institute for Translational Cancer Research. She leads a research group focused on Immune Cell Signaling in Chronic Lymphocytic Leukemia (CLL), investigating the molecular mechanisms of B cell signaling dysregulation in cancer.
Her research interests center on the divergent signaling events in malignant versus normal B cells, particularly downstream of the B cell receptor. She studies how negative regulators such as SHIP1 and DUSP6 modulate PI3K/AKT and MAPK pathways in CLL. Her work has demonstrated that hyperactivation of these pathways can induce immunogenic cell death, offering new therapeutic strategies for drug-resistant CLL and Richter’s transformation.
Her recent publications reveal a consistent focus on exploiting signaling imbalances in leukemia for therapeutic benefit, with strong emphasis on phosphatase inhibition, mitochondrial metabolism, and the DNA damage response. This body of work positions her at the forefront of translational cancer signaling research.
Scientific Awards:
- Max-Eder Fellowship, German Cancer Aid (2016, 2022)
- Abstract Achievement Award, American Society of Hematology (2012, 2013, 2015)
- DAAD Rückkehrer Stipendium (2014)
- Award for outstanding achievements, University Medical School Freiburg (2010)
- PhD Scholarship, University Medical School Freiburg (2006)
Dr. Buchner has secured competitive grant funding and leads an independent research program. Her work involves collaboration with clinical and preclinical teams, utilizing patient samples and advanced proteomic techniques. She is actively contributing to the development of novel therapeutic approaches in CLL and is embedded in a strong translational research environment at TUM.
She is affiliated with TranslaTUM, where her lab investigates signaling pathways in the context of cancer immunology and therapy resistance. Her research group integrates molecular biology, signaling analysis, and translational models to uncover new vulnerabilities in leukemia cells.
